26 results
Thumbnail

D2.308 - Diet quality and intake behaviours among alpha-gal–positive patients at a specialized allergy clinic in Sri Lanka

Thumbnail

D2.317 - “Cutaneous Anaphylaxis to Raw Egg White in a Patient with Established Oral Tolerance: Clinical Evidence Supporting the Dual-Allergen-Exposure Hypothesis”

Thumbnail

D2.318 - Don`t miss the cannabis-associated food syndrome (CAFS)

Thumbnail

D2.303 - The effect of extrusion on the in vivo allergenicity of pistachio and walnut in allergic children

Thumbnail

D2.304 - Allergy and Exercise: A Sporting Challenge

Thumbnail

D2.305 - Alpha-gal syndrome

Thumbnail

D2.306 - From baked cookie to unheated milk: Desensitization in a high-risk cow’s milk protein allergy patient

Thumbnail

D2.307 - Parental and Healthcare Professional Experiences of Food Allergen Introduction during Complementary Feeding: A Behavioural Theory–Informed Systematic Review

Thumbnail

D2.309 - HAL-MPE1, a novel subcutaneous immunotherapy candidate for peanut allergy. Phase I randomized placebo-controlled study

Thumbnail

D2.313 - Scientific Evidence Gaps in FAO/WHO Food Allergen Threshold Guidance: Implications for Risk Assessment and Regulatory Decision-Making

Thumbnail

D2.315 - Clinical Characteristics and Diagnostic Challenges in Pediatric Peanut and Tree Nut Allergies: The Impact of Unnecessary Elimination

Thumbnail

D2.316 - Novel Homozygous Mutation in CARD11 gene Predisposing To Recurrent Infections and Atopies, and Response to Immunoglobulin therapy

Thumbnail

D1.105 - Real-Life Evidence of Type 2 Immunomodulation with Benralizumab: From Steroid-Dependent to Controlled Asthma

Thumbnail

D1.106 - Dupilumab-Induced Systemic Eosinophilic Immune Activation Mimicking an EGPA-Like Prodrome: A Case Report

Thumbnail

D1.108 - Optimization of phenotyping in severe T2-bronchial asthma

Thumbnail

D1.109 - Biologics selection algorithm for severe T2-bronchial asthma targeted therapy

Thumbnail

D1.110 - Long Term Mepolizumab in Type-2 CRSwNP: Marked Polyp Reduction, Symptom Relief, and Airway Benefits in Real World Comorbid Patients

Thumbnail

D1.111 - Tezepelumab reduces in patients with severe allergic asthma and rhinoconjunctivitis not only bronchial but also nasal and conjunctival symptoms – results from an exposure chamber study

Thumbnail

D1.112 - ILC2 Expansion as a Biomarker of Suboptimal Response to Dupilumab in Severe Asthma: Findings from the PRISM Study

Thumbnail

D1.113 - Effect of mepolizumab in eosinophilic granulomatosis with polyangiitis (EGPA): a real-world retrospective observational study